Calendar

Week of Apr 27, 2026

Apr 30, 2026phase 1 2 completion114d agoUniversity Hospital Geneva — verteporfin (Phase I/II Trial Completion)verteporfin

Therapy area: Dermatology, Infectious Disease, Oncology. Indication: Melanoma, Scar, Surgical Wound Infections

full page →verteporfin →source: globaldata

Apr 30, 2026phase 1 2 completion114d agoCentre International de Développement Pharmaceutique — afamelanotide (Phase I/II Trial Completion)afamelanotide

Therapy area: Dermatology. Indication: Vitiligo

full page →afamelanotide →source: globaldata

Apr 30, 2026phase 2 completion114d agoUsynova Pharmaceuticals Ltd — UA-021 (Phase II Trial Completion)UA-021

Therapy area: Immunology. Indication: Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis

full page →UA-021 →source: globaldata

Apr 30, 2026phase 2 completion114d agoVaidya Yagya Dutt Sharma Ayurvedic P. G. Mahavidhyalaya — ayurvedic medicine (Phase II Trial Completion)ayurvedic medicine

Therapy area: Dermatology. Indication: Burns

full page →ayurvedic medicine →source: globaldata

Apr 30, 2026phase 2 completion114d agoZhejiang Provincial People's Hospital — telitacicept (Phase II Trial Completion)telitacicept

Therapy area: Immunology. Indication: Rheumatoid Arthritis

full page →telitacicept →source: globaldata

Apr 30, 2026phase 2 completion114d agoQinghai Provincial Xining Third People's Hospital — amoxicillin (Phase II Trial Completion)amoxicillin

Therapy area: Gastrointestinal, Infectious Disease. Indication: Gastritis, Helicobacter pylori Infections

full page →amoxicillin →source: globaldata

Apr 30, 2026phase 2 completion114d agoGuy's and St Thomas' NHS Foundation Trust — autologous regulatory T cells (Phase II Trial Completion)autologous regulatory T cells

Therapy area: Genito Urinary System, Immunology. Indication: End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Kidney Transplant Rejection

full page →autologous regulatory T cells →source: globaldata

Apr 30, 2026phase 2 completion114d agoMerck & Co Inc — tulisokibart (Phase II Trial Completion)tulisokibart

Therapy area: Immunology, Respiratory. Indication: Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Systemic Sclerosis (Scleroderma)

full page →tulisokibart →source: globaldata

Apr 30, 2026phase 2 completion114d agoNigde Omer Halisdemir University — ozonated oil (Phase II Trial Completion)ozonated oil

Therapy area: Dermatology, Gastrointestinal, Immunology. Indication: Inflammation, Inguinal Hernia, Wounds

full page →ozonated oil →source: globaldata

Apr 30, 2026phase 2 completion114d agoAssaf Harofeh Medical Center — acetaminophen (Phase II Trial Completion)acetaminophen ER

Therapy area: Central Nervous System. Indication: Pain

full page →acetaminophen ER →source: globaldata

Apr 30, 2026phase 2 completion114d agoNational Institutes of Health — metformin hydrochloride ER (Phase II Trial Completion)metformin hydrochloride ER

Therapy area: Cardiovascular, Genito Urinary System, Infectious Disease. Indication: Acute Renal Failure (ARF) (Acute Kidney Injury), Sepsis, Septic Shock

full page →metformin hydrochloride ER →source: globaldata

Apr 30, 2026phase 2 completion114d agoRenji Hospital — norepinephrine (Phase II Trial Completion)norepinephrine

Therapy area: Genito Urinary System, Immunology. Indication: Delayed Graft Function (DGF), End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)

full page →norepinephrine →source: globaldata

Apr 30, 2026phase 2 completion114d agoBeijing Jishuitan Hospital — undisclosed anesthetic drug (Phase II Trial Completion)undisclosed anesthetic drug

Therapy area: Central Nervous System, Musculoskeletal Disorders. Indication: Bone Fracture, Pain

full page →undisclosed anesthetic drug →source: globaldata

Apr 30, 2026phase 2 completion114d agoJetema Co Ltd — JTM-102 (Phase II Trial Completion)JTM-102

Therapy area: Dermatology. Indication: Unspecified Dermatological Disorders

full page →JTM-102 →source: globaldata

Apr 30, 2026phase 2 completion114d agoNanjing First Hospital — amoxicillin (Phase II Trial Completion)amoxicillin

Therapy area: Infectious Disease. Indication: Helicobacter pylori Infections

full page →amoxicillin →source: globaldata

Apr 30, 2026phase 2 completion114d agoChinese Academy of Medical Sciences Plastic Surgery Hospital — recombinant type III humanized collagen (Phase II Trial Completion)recombinant type III humanized collagen

Therapy area: Dermatology. Indication: Crow Feet, Unspecified Dermatological Disorders, Wrinkles, Xerosis (Dry Skin)

full page →recombinant type III humanized collagen →source: globaldata

Apr 30, 2026phase 2 completion114d agoSunstar Inc — SSJG-009 (Phase II Trial Completion)SSJG-009

Therapy area: Immunology. Indication: Inflammation

full page →SSJG-009 →source: globaldata

Apr 30, 2026phase 2 completion114d agoInstituto de Investigacion sanitaria de Santiago de Compostela — Vacucis (Phase II Trial Completion)Vacucis

Therapy area: Infectious Disease, Mouth and Dental Disorders. Indication: Candidiasis, Xerostomia

full page →Vacucis →source: globaldata

Apr 30, 2026phase 2 completion114d agoPolice General Hospital — acetaminophen (Phase II Trial Completion)acetaminophen ER

Therapy area: Central Nervous System, Women's Health. Indication: Labor And Delivery, Pain

full page →acetaminophen ER →source: globaldata

← prev

page 3 of 3

Week of Apr 27, 2026